Company research
ANAPTYSBIO, INC
CIK 1370053Updated Sep 24, 2026
SecurityANAB · NASDAQ · equity
Name history
ANAPTYSBIO INC · through Jun 12, 2019ANAPTYS BIOSCIENCES INC · through Nov 20, 2007
ANAB price & chart
Loading TradingView…
NASDAQ:ANAB on TradingView ↗About the company
Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www. AnaptysBio.com or follow us on LinkedIn.
In the news
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference ↗
Recent filings
10-KT filing
Financial Statements and Exhibits
Items 9.01
SCHEDULE 13G/A filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Regulation FD Disclosure
Items 7.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 316,984,000Source | 364,395,000Source | 483,834,000Source | 452,389,000Source |
| Property, Plant and Equipment, NetUSD | 102,000Source | 1,370,000Source | 1,849,000Source | 2,098,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 133,826,000Source | 238,196,000Source | 123,080,000Source | 35,965,000Source |
| Assets, CurrentUSD | 198,427,000Source | 350,250,000Source | 431,876,000Source | 406,835,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,650,000Source | 4,762,000Source | 5,738,000Source | 9,080,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,560,000Source | 12,519,000Source | 14,383,000Source | 16,174,000Source |
| Other Assets, NoncurrentUSD | 256,000Source | 256,000Source | 256,000Source | 256,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 30,000Source | 28,000Source | 30,000Source | 27,000Source |
| Additional Paid in CapitalUSD | 652,269,000Source | 809,765,000Source | 829,860,000Source | 702,969,000Source |
| Retained Earnings (Accumulated Deficit)USD | -641,563,000Source | -772,559,000Source | -759,327,000Source | -614,096,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -151,000Source | -24,000Source | 305,000Source | -797,000Source |
| Stockholders' Equity Attributable to ParentUSD | 10,585,000Source | 37,210,000Source | 70,868,000Source | 88,103,000Source |
| Liabilities and EquityUSD | 316,984,000Source | 364,395,000Source | 483,834,000Source | 452,389,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 35,353,000Source | 38,625,000Source | 45,428,000Source | 37,442,000Source |
| Operating Lease, Liability, CurrentUSD | 2,161,000Source | 2,080,000Source | 1,925,000Source | 1,777,000Source |
| Accounts Payable, CurrentUSD | 4,394,000Source | 3,871,000Source | 4,002,000Source | 4,698,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,934,000Source | 12,032,000Source | 14,112,000Source | 16,037,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 28,798,000Source | 32,674,000Source | 39,501,000Source | 30,967,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 559,000Source | 606,000Source | 652,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | 36,072,000Source | 34,048,000Source | 33,205,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | 19,697,000Source | -135,337,000Source | -120,800,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 228,032,000Source | 95,398,000Source | 144,754,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 87,000Source | 358,000Source | 807,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 1,451,000Source | 7,504,000Source | — |
| Payments for Repurchase of Common StockUSD | — | 68,626,000Source | 456,000Source | 50,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | -132,613,000Source | 127,054,000Source | -59,297,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | 115,116,000Source | 87,115,000Source | -35,343,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 133,826,000Source | 238,196,000Source | 123,080,000Source | 35,965,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 79,994,000Source | 42,132,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 36,072,000Source | 34,048,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | 50,737,000Source | 42,389,000Source | 41,946,000Source |
| Income Tax Expense (Benefit)USD | — | 164,000Source | 3,000Source | -4,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | -13,232,000Source | -145,231,000Source | -163,619,000Source |
| Nonoperating Income (Expense)USD | — | -60,964,000Source | -30,279,000Source | 788,000Source |
| Operating ExpensesUSD | — | 186,707,000Source | 206,229,000Source | 181,568,000Source |
| Other Nonoperating Income (Expense)USD | — | 5,430,000Source | 14,000Source | -2,000Source |
| Proceeds from Issuance of Common StockUSD | — | 14,261,000Source | 6,473,000Source | 2,472,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 12,900,000Source | 5,300,000Source | 1,800,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | 4,734,000Source | 10,313,000Source | 10,521,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 234,603,000Source | 91,280,000Source | 17,157,000Source | 10,287,000Source |
| Operating Income (Loss)USD | 47,896,000Source | -114,949,000Source | -164,411,000Source | -115,154,000Source |
| Other Nonoperating Income (Expense)USD | 5,430,000Source | 14,000Source | -2,000Source | 12,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -13,068,000Source | -145,228,000Source | -163,623,000Source | -128,700,000Source |
| Income Tax Expense (Benefit)USD | 164,000Source | 3,000Source | -4,000Source | 24,000Source |
| Net Income (Loss) Attributable to ParentUSD | -13,232,000Source | -145,231,000Source | -163,619,000Source | -128,724,000Source |
| Earnings Per Share, BasicUSD per share | -0.46Source | -5.12Source | -6.08Source | -4.57Source |
| Earnings Per Share, DilutedUSD per share | -0.46Source | -5.12Source | -6.08Source | -4.57Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 28,758,000Source | 28,382,000Source | 26,924,000Source | 28,165,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 28,758,000Source | 28,382,000Source | 26,924,000Source | 28,165,000Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 50,737,000Source | 42,389,000Source | 41,946,000Source | 36,643,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -13,068,000Source | -145,367,000Source | -163,580,000Source | -128,650,000Source |
| Interest Income, OtherUSD | 13,499,000Source | 19,794,000Source | 18,873,000Source | 7,550,000Source |
| Nonoperating Income (Expense)USD | -60,964,000Source | -30,279,000Source | 788,000Source | -13,546,000Source |
| Operating ExpensesUSD | 186,707,000Source | 206,229,000Source | 181,568,000Source | 125,441,000Source |
| Research and Development ExpenseUSD | — | — | — | 88,798,000Source |
Filing attachments
anab-ex99_1.htm · 8-K · 2026-09-21
Exhibit 99.1 Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update • Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth • Positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review…
Read attachment ↗anab-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 anab-ex99_1.htm EX-99.1 EX-99.1 Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update • Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business • Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda • Announced appointment of Chris Murphy as CFO • Announced appointments of Susannah Gray, former CFO of Royalty Pharma, and Owen Hughes, current CEO of XOMA Roy…
Read attachment ↗d104779dex991.htm · 8-K/A · 2026-04-24
EX-99.1 2 d104779dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Spin-Off of First Tracks Biotherapeutics On April 20, 2026 (the “Distribution Date”), AnaptysBio, Inc. (the “Company” or “AnaptysBio”) completed the separation of its biopharma operations by means of a spin-off (the “Spin-Off”) into a new, independent public company, First Tracks Biotherapeutics, Inc. (“First Tracks”). Unaudited Pro Forma Condensed Consolidated Finan…
Read attachment ↗d120122dex991.htm · 8-K · 2026-04-20
EX-99.1 4 d120122dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholders Launches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, CA - April 20, 2026 - AnaptysBio, Inc. (Nasdaq: ANAB), a royal…
Read attachment ↗d122216dex991.htm · 8-K · 2026-03-27
EX-99.1 4 d122216dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics Board sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-market ─────────────────────────────────────────────────────────────────────────── Stockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio common stock owned First Tracks Bio initial cash b…
Read attachment ↗d122216dex992.htm · 8-K · 2026-03-27
EX-99.2 5 d122216dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement Inclusive of $80 million in proceeds from private placement by leading investors First Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, CA - March 27, 2026 - AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, I…
Read attachment ↗